Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02978417 · ClinicalTrials.gov registry record · Phase 4
Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings
A Phase 4 study of Opioid-Related Disorders, sponsored by Duke University.
- Completed
- Registry status
- Phase 4
- Development phase
- 14
- Enrollment target
- 1
- Study location
NCT02978417: Completed Phase 4 study of Opioid-Related Disorders, sponsored by Duke University.
NCT02978417 is a Phase 4 study of Opioid-Related Disorders that has completed, run by Duke University. The registered enrollment target is 14 participants, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02978417, a Phase 4 study of Opioid-Related Disorders, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 14 participants
- Enrollment target
- 1
- Study location
Study Summary
In preparation for a large-scale randomized controlled trial (RCT) of Vivitrol® effectiveness in drug courts, investigators propose a feasibility study in the Wake County, North Carolina drug court, where an estimated 50% of clients are opioid dependent. Aim 1: Pilot RCT. Pilot-test the delivery of Vivitrol® treatment for 10-20 interested and eligible clients of the Wake County Drug Court.
Primary Outcome
Any new arrests during the 12-month study period. This information will be collected from administrative records.
Conditions Studied
Interventions
- DRUG Naltrexone for extended-release injectable suspension
- DRUG Oral naltrexone
Study Locations (1)
North Carolina
- Fellowship Health Resources (FHR) - Raleigh
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2017-09-21 |
| Est. Completion | 2019-06-30 |
| Phase | Phase 4 |
What the finished NCT02978417 record still lists
NCT02978417 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 347-participant average among 47 other Opioid-Related Disorders trials with a reported enrollment target (96% lower).
The record links to 1 condition, with Opioid-Related Disorders appearing as the primary indexed condition, and to 2 interventions - of which Naltrexone for extended-release injectable suspension is the first listed.
NCT02978417 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02978417 about?
NCT02978417 is a clinical study titled "Feasibility Study of Extended-release Naltrexone (Vivitrol) in Drug Court Settings". In preparation for a large-scale randomized controlled trial (RCT) of Vivitrol® effectiveness in drug courts, investigators propose a feasibility study in the Wake County, North Carolina drug court, where an estimated 50% of clients are opioid dependent. Aim 1: Pilot RCT. Pilot-test the delivery of...
What is the current status of trial NCT02978417?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 14 participants. The study started on 2017-09-21. Estimated completion is 2019-06-30.
What conditions does trial NCT02978417 study?
This clinical trial studies the following conditions: Opioid-Related Disorders.
What interventions are being tested in trial NCT02978417?
The interventions under investigation include: Naltrexone for extended-release injectable suspension (DRUG), Oral naltrexone (DRUG).
Who is sponsoring clinical trial NCT02978417?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02978417 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Opioid-Related Disorders
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02978417's enrollment target sits among peer trials
14 41st of 47 higher than 6 of 47 other Opioid-Related Disorders trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Opioid-Related Disorders trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility Study of Take-Home LAAM Medication - 3
COMPLETED · Phase 4
-
The Kentucky Viral Hepatitis Treatment Study
COMPLETED · Phase 4
-
Psilocybin in Cancer Pain Study
RECRUITING · Phase 2
-
Developing and Evaluating a Machine-Learning Opioid Overdose Prediction & Risk-Stratification Tool in Primary Care
RECRUITING · NA
-
Developing a Smartphone Application to Support Veteran Opioid Use Disorder Treatment
RECRUITING · NA
-
Neurocognitive Mechanisms Underlying Smartphone-Assisted Prevention of Relapse in Opioid Use Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy